### Index

Note: Illustrations are comprehensively referred to in the text. Therefore, significant material in illustrations has usually been given a page reference only in the absence of its concomitant mention in the text referring to that figure. Page references to figures are in italic and those to tables are in bold.

| A | abnormalities (general aspects) | assessment of 19 |
| | description of 79 |
| | seen on one view only, MRI with 169 |
| | abscess 321–326 |
| | males 572 |
| | accessory breast tissue 244 |
| | accuracy biopsy 187–189, 189 |
| | mammography 22 |
| | DCIS 379 |
| | fibroadenoma 297–298 |
| | MRI 128–129 |
| | augmented breast and implant complications 162 |
| | cysts 282 |
| | DCIS 384–385 |
| | fibroadenoma 304 |
| | in preoperative local staging 156–158, 396 |
| | in problem-solving after conserving therapy 159 |
| | in problem-solving after reconstruction 162 |
| | sonography carcinoma 440–441 |
| | cysts 281 |
| | DCIS 381 |
| | fibroadenoma 299–304 |
| | acoustic shadows see shadowing |
| | ACR see American College of Radiology |
| | add-on units in stereotactic biopsy 203 |
| | adenofibrolipoma 290 |
| | adenofibroma 292–306 |
| | adenoma 292, 293 |
| | nipple 349 |
| | adenomyoepithelioma 480 |
| | adenosis 257 |
| | cystic 650 |
| | nodular 263, 608 |
| | sclerosing 266, 268, 620, 650 |
| | adolescent breast 235 |
| | age 241–242 |
| | changes with 241–242 |
| | mammographic density and cancer risk related to 258 |
| | screening mammography 50, 581, 663, 666 |
| | screening MRI 154 |
| | allergy and hypersensitivity contrast media 86 |
| | local anesthetic 192 |
| | American College of Radiology (ACR) on mammography |
| | benign disorders 258 |
| | BI-RADS see BI-RADS density/parenchymal pattern (ACR1–4) 8, 9, 79, 241, 258, 259 |
| | equipment/hardware 74, 75 |
| | label abbreviations for breast positioning 62 |
| | on MRI 134–135, 148 |
| | amorphous selenium 34–35 |
| | amorphous silicon 35–36 |
| | amyloidosis 310 |
| | anatomy breast see normal breast |
| | lymph nodes 459 |
| | angiolipoma 308 |
| | angiomas 308–309 |
| | angiomatosis 308 |
| | angiosarcoma 308, 480, 481, 482, 484 |
| | anisomastia 242 |
| | anticoagulants and biopsy 192, 192–193 |
| | antiestrogen therapy 403 |
| | anxiety in biopsy 192 |
| | apparent diffusion coefficient 132, 181–182 |
| | architectural distortion 615–625 |
| | biopsy performed due to 212 |
| | differential diagnosis 431–432, 615–625 |
| | mammography 82, 431–432 |
| | carcinoma 406, 407, 439 |
| | radial scar 261 |
| | scar 649 |
| | radial 261 |
| | sonography 113, 121 |
| | carcinoma 433 |
| | areola area behind/under see subareolar/retroareolar region |
| | in Paget disease 404 |
| | artifacts mammography mimicking calcifications 646 |
| | responsibility for evaluation of 77 |
| | MRI, cardiac 144–145 |
| | aspirated cyst see cysts assessment of imaging 186 |
| | clinical abnormalities 19 |
| | pathognomonic findings and 595–596 |
| | state-of-the-art 595–596 |
| | asymmetry see symmetry |
| | asymptomatic women with breast cancer, lower axilla examination 104 |
| | with dense breast tissue 632–633 |
| | with intermediate or high risk 633 |
| | MRI 269–272, 632–633, 633 |
| | global mammographic asymmetry in 626 |
| | intramammary lymph nodes 311 |
| | screening see screening attenuation |
| | mammography/X-rays 75 |
| | carcinoma 405–407 |
| | sonography, carcinoma 433–439 |
| | atypia (cellular) 188 |
| | benign proliferative lesions 272 |
| | flat epithelial (columnar cell hyperplasia with atypia) 338, 341–345 |
| | atypical intraductal ductal epithelial proliferations 338, 340–346, 366, 621 |
| | atypical lobular hyperplasia (ALH) 345–346 |
| | augmented breasts see implanted/augmented breasts |
| | autogenous tissue transfer 509 |
| | autoimmune granulomatous disorders 327, 327–328, 328, 329, 331, 334 |
automated whole breast ultrasound 181
automatic exposure control systems 30–33, 47, 75
manual adjustment 47, 75
performance assessment 77
quality of 75
axial resolution in sonography 102
axilla ectopic glandular tissue 19, 244
MRI of benign lesions 143
sonography 99–100, 186, 596
in biopsy guidance 197
examination 103–104
normal findings 113
suspicious findings 124
axillary lymph nodes see lymph nodes
axillary view 60

B
B3 lesions (of BI-RADS) see uncertain malignant potential
bar pattern 74
basal-type carcinoma 401, 402
benign disorders/lesions (non-neoplastic or in general) 255–274
biopsy 272
calcifications with see calcifications
classification 260
clinical examination/findings 258, 272, 273
definition 256
diagnostic strategy and objectives 260–261
European guidelines for classification of lesions 211
histopathology 256–258, 272
incidence 256
lymphadenopathy due to 329, 469
males 571–572
mammography 261–266, 272
BI-RADS categorization 83
density and risk 258–260, 261–265, 272
MRI 268–272, 272
BI-RADS categorization 151
pathogenesis 256
pathognomonic finding of 594–595
sonography 266–268, 272
BI-RADS categorization 123
lesions with high/very high probability of benignity 118–120
males 571–572
in younger patients 665
in pregnancy 664–665
benign tumors 289–293
phyllodes tumor as 476, 479
rare 306–309
biopsy, ductoscopic, nipple discharge and papillary lesions 350
biopsy, percutaneous (for histopathology) 185–214, 596
abscesses 326
accuracy 187–189, 189
B3 lesions (of uncertain malignant potential) 340
atypical intraductal epithelial proliferations 340–341
fibroepithelial lesions 360, 479
lobular neoplasia and proliferations 346, 368–370
papillary lesions 354
radial scar 190, 346, 348
benign non-neoplastic disorders 272
benign tumors/tumor-like lesions fibroadenoma 298
focal fibrosis 310
hamartoma 290, 304
intramammary lymph nodes 312
rare types 306
calcifications 643
sonographic guidance 189
care following 193
complications 192
contraindications 192
DCIS 385
fistulas 326
granulomatous lesions 334
guidance see guidance
HRT and 248
indications 191–192
inflammatory change 663
in local preoperative staging 157
lymph nodes 471
sentinel 398, 458
malignancy/semi-malignancy carcinoma see carcinoma hematologic tumors 486
metastases (in breast) 489
phyllodes tumor 360, 479
sarcoma 484
MRI not recommended over 151–152
of palpable lesions in dense breast 636–640
patient information 5, 192
patient information/preparation 192
possibilities/limitations 189–192
techniques 193–212
trauma (incl. surgery)-related changes 507
conserving therapy + irradiation 529
reduction mammoplasty 507
types/methods 187
choice 189–192
see also specific types
vacuum-assisted see vacuum-assisted biopsy
younger patient 670–672, 672
see also specimen
biopsy, surgical/excisional/non-percutaneous 191, 597
B3 lesions (of uncertain malignant potential)
atypical ductal hyperplasia 341
atypical ductal hyperplasia flat epithelial atypia 343
lobular neoplasia and proliferations 346
fibroadenoma 298
mastitis 319
skin thickening 561
“biopsy” coils 216
BI-RADS (Breast Imaging Reporting and Data System)
B3 see uncertain malignant potential
mammography 79, 83–85, 186
density 80
mass 80
MRI 144, 147, 151
phyllodes tumor and 476
sonography 127
bizarre calcifications 651, 658, 659
bleeding/hemorrhage 504
in preoperative localization 217
see also hyperemia
blood vessel (vascular) calcifications 651
blurring see sharpness or blurring
body mass index as risk factor 10
borderline lesions 210
atypical ductal hyperplasia as 340
phyllodes tumor as 356, 476
see also uncertain malignant potential
BRCA1 and BRAC2 (cancers linked to) 392, 403
breast calcifications and microcalcifications 642–657
analysis 643–657, 651
algorithm 644–645
benign causes 256, 265–266, 644, 645, 646–651, 656
fibroadenoma 293–298, 299
granulomatous lesions 328
typical benign calcifications 644
differential diagnosis 642–657
regression on turning into invasive malignancy 420
in views
90° lateral view 58
tangential view, subcutaneous calcifications 60
lymph node 469–471
with metastases 466, 471
malignancy/cancer/
carcinoma 399, 406, 420, 501, 655, 658, 659, 670
differentiation from benign changes 431
diffusely growing 420
focally growing 416–417
hereditary 430
males 569
recurrences (after conserving therapy + radiation) 523
signs suggesting malignancy 644, 645, 651–656
mammography 642
sonographic guidance of biopsy following 189
MRI 272, 643
newly developing 654
reporting and documentation 82–83
of decreases 79
sharpness 41
sonography of 641
BI-RADS and 123
in biopsy guidance of mammographically detected 189
specimen radiography 73, 206
stereotactic biopsy 206
teacup 58, 265, 650, 651, 656
trauma (incl. surgery)-related changes 495–504
conserving surgery with irradiation 517–523
reduction mammoplasty 507
uncharacteristic 643, 656–657
Canadian randomized controlled trials of screening 580
cancer
breast
carcinoma see carcinoma
other than primary carcinoma 475–491
childhood 9
ovarian see ovarian cancer
capsule, fibrous (with implants) contracture 541–542
herniation 542
rupture of 544
rupture within 542–544
carbon solution as preoperative localization marker 226
carcinoma, invasive (often referred to in text as “malignancy” or “cancer”) 391–455, 475–491
benign disorders and risk of 250
in BI-RADS (≥ B5) 211
biopsy (percutaneous) for 191, 395, 445, 448–450, 450
males 569
calcifications see calcifications clinical examination 403
clinical manifestations 402
definition 392–393
diagnosis/detection 98–99, 394–400, 432, 441, 448–450
differential see subheading below
problems posted 392–393
spectrum and 393–394
strategy and goals 394–400
differential diagnosis 431–432, 440–441
scars 495
epidemiology 392
etiology 392
extent/degree of extension 397
MRI correlations with 444–445
widespread, signs suggesting 417
frequent types 400–401
grading 393
hereditary see hereditary/familial cancer
histopathology 400–403, 448
males 567
mammographic presentation influenced by 428–430
sonographic image presentation correlating with 440
inflammatory change 432, 662
interval see interval cancer
males 567–571, 572
mammography 393, 394–395, 405–432, 450
MRI, screening see screening MRI
BI-RADS categorization 83–85
in differential diagnosis 431–432
extent of tumor 397
follow-up or prior studies 420–428
histopathology influencing 428–430
implanted breast 538, 548, 550, 551
males 569, 569–571
neoadjuvant chemotherapy monitoring 399
sensitivity and specificity 431
younger patient 666, 668, 669
MRI 135, 136, 137, 138, 139, 441–448, 450
absence of enhancement excluding malignancy with high probability 144
BI-RADS categorization 151
contrast-enhanced 393
density 405–407
diagnostic role 441
extent of tumor 397
indications 445–446
for local staging (preoperative) 156–158, 396
neoadjuvant chemotherapy monitoring 166, 399–400, 448
post-reconstructive surgery 159–160
variations and pitfalls 445
palpation problems 19
precursors see precursors; uncertain malignant potential in pregnancy and lactation 665
Index

prognosis 402–403
  prognostically very favorable cancers 587
rare types 401–402
recurrence see recurrence
risk factors see risk factors
sonography 268, 393, 394–395, 432–441, 450
advantages and limitations 438
BI-RADS categorization 123
diagnostic role or value 98–99, 432
extent of tumor 397
features with highest positive predictive value 118
image presentation 433–440
indications 432
lower axilla examination in asymptomatic women with breast cancer 104
males 569, 571
mammography
  complementing 430
  neoadjuvant chemotherapy monitoring 399
younger patient 669, 670
staging see staging
symptoms hinting of 11
therapy
  changes caused by 11, 493–531
  chemotherapy see chemotherapy
  conservation see conservation screening and its favorable impact on 588
unknown primary see primary tumor, unknown
younger patient 663–668
clinical findings 665–672
diagnostic difficulties 663
presentation 664
risk 665
see also borderline lesions;
metastases and specific types of carcinoma

carcinoma in situ
  (and intraepithelial neoplasia) 365–388
carcinomas (rare types)
  vs 401–402
definition/terminology/biological concept 366
ductal see ductal carcinoma in situ
histology see histopathology lobular 338, 345–346, 366–370, 386
MRI see magnetic resonance imaging
cardiac artifacts in MRI 144–145
casting microcalcifications 373–375, 651
DCIS 373–375, 654
characteristic curve (film) 30
charge-coupled devices 38
chemotherapy
  neoadjuvant see chemotherapy
  screening reducing need for 588
chest wall injury in preoperative localization 217
childhood cancer 9
  radiation treatment 9
chondroma 306
Churg–Strauss syndrome 328
circumscribed skin changes 17
cleavage view 60
clinical examination and findings see examination and findings
clip marking
  biopsy
    core needle 194–195
    stereotactic 206
  vacuum-assisted 195–197
  preoperative localization 227
residual tumor after neoadjuvant chemotherapy 399
clustered calcifications 657
coaxial system in biopsy
  in core needle biopsy 194
  in MR-guided biopsy 207–210
collagen injections for augmentation 535
collimation assessment 77
colloid lesions see mucinous lesions
  color Doppler 181
  columnar cell hyperplasia with atypia 338, 341–345
  comedo-type DCIS 375, 384, 418, 643
  calcifications 652, 655
  communication with patient see information
  complex cystic lesions 118
  complex sclerosing lesion see radial scar
compound imaging
  (sonography) 102
  compressibility/elasticity, assessment see elastography
  compression (mammography) 29, 45, 52–54
  blurring avoidance 40
calcifications and adequacy of 642
craniocaudal view 55
exaggerated medial 60
implanted breasts 71
mediolateral oblique view 54
scattering reduced by 29, 45
semiannual tests 78
of specimen 73
spot 60, 62–64, 70
compression (sonography)
  assessment of compressibility see elastography
  slight 103
compression plate 217–218
computed radiography 36–37
computed tomography
  lymph nodes, combined with PET 473
preoperative localization guided by 222
computer-aided diagnosis/detection 40
in digital tomosynthesis 179
conservation (therapy/surgery) 512–529
calcifications 499, 512, 513, 514, 517–523, 528
ductal carcinoma in situ 372
recurrence risk 371
HRT after 248
with irradiation 512–529
without irradiation 512
neoadjuvant chemotherapy and 162, 163
problem solving after 158–159
contraceptive pills see oral contraceptives
carinal breast
  comparisons with 251, 420
  malignancy in 396, 398
  metastases from 487, 489
contrast (mammographic image) 26–29, 41–49
determining factors 44–49
  compression 45, 53
developing time extension causing increase in 49
  high but not excessive 43, 48
  low 43
in magnification mammography, decreased 70
screen–film systems and 30
contrast (sonographic image), resolution 102
contrast-enhanced digital mammography 180
contrast-enhanced MRI (incl. dynamic contrast-enhanced MRI) 128–175
Index

fibroepithelial lesions 356–360, 466–469
lobular neoplasia 368–370
papillary lesions and nipple discharge 350–354
benign non-neoplastic disorders (in general) 260–261
benign tumors/tumor-like lesions fibroadenoma 293–305
hamartoma 290
intramammary lymph nodes 312
lipoma 306
computer-aided see computer-aided diagnosis
cysts see cysts
differential see differential diagnosis
ductal carcinoma in situ 372–385
early, positioning for mammography and its importance in 56–57
final 83–85
fistulas 321–325
granulomatous conditions 328–334
gynecomastia 565–566
lymph node involvement 398–399, 459
malignancy/semi-malignancy carcinoma see carcinoma
hematologic tumors 485–486
males 569–571
metastases (in breast) 487
overdiagnosis in screening 482, 585–586
phyllodes tumor 356–360, 466–469
sarcoma 480–484
mastitis 317
skin
nodular changes 554
thickening 555
trauma (incl. surgery)-related changes 494–507
conserving surgery with irradiation 513–529
conserving surgery without irradiation 512
reconstructive surgery 509
reduction mammoplasty 507
DICOM (Digital Imaging and Communications in Medicine) 40
Grayscale Standard Display Function 39
dietary (nutritional) risk factors 8, 10
differential diagnosis 597–671
architectural distortion 431–432, 615–625
benign disorders on MRI 269–272
calcifications 642–657
carcinoma see carcinoma
cysts 276, 281, 599–602
ill-defined/not smoothly outlined mass 604–615
lipoma 306
mammographically dense breast 632–640
nipple retraction 640
pain 640
skin thickening 555, 561
smoothly outlined density 597–604
trauma (incl. surgery)-related changes 495
conserving therapy without irradiation 512
reduction mammoplasty 507
younger patients with very large masses 665
diffuse architectural distortion, differential diagnosis 431–432
diffuse changes
asymmetry and 632
benign 272, 273
biopsy of 212
conserving surgery with irradiation
mammography 514
sonography 523
differential diagnosis 431
diffuse enhancement (on MRI) 269
carcinoma 400, 441–444
milky 237, 269
nonmass 149–150
diffuse fibrosis 258
diffuse glandular gynecomastia 566
diffuse growth pattern
hematologic tumors 486
invasive carcinoma,
mammography 422, 423, 424
calcification 655
histology influencing mammographic presentation 430
recurrences (after conserving therapy + radiation) 523
signs 405, 420
metastases in breast 487, 489
diffuse skin changes (incl. thickening) 555
carcinoma 404
differential diagnosis 432
diffusion-weighted MRI 132, 181–182
neoadjuvant chemotherapy monitoring 166, 400
Digital Imaging and Communications in Medicine, see also DICOM
digital mammography 33–39
calcifications 642
contrast 43
contrast-enhanced 180
dose and optimization of 52
image quality factors
exposure 75
resolution 74
sharpness 41
structural noise 49
tomosynthesis combined with see tomosynthesis
discharge, nipple 657–661
bilateral bloodless 86
galactography 86, 660
MRI compared with 169
observing 11
pathologic 86, 657–661
benign 258
cancer 404–405, 430
DCIS 379
definition 657
diagnostic problems 657–660
diagnostic strategy 660–661
papillary lesions 349–350
younger patients 665
display monitors 38
distribution patterns
benign disorders in mammography
atypical 261
typical 261, 265
calcifications 643
suggesting malignancy 651–656
documentation/recording/reporting
location of lesion 186, 227
mammography
findings 78–85
of quality control 77
sonography 105–124
US-guided biopsy 203
Doppler imaging
color 181
lipophagic granuloma 526
power 107–109
dose 50–52
compression enabling reduction in 53
noise with low-dose screen–film systems 48, 49
optimization/minimization 51
responsibility for assessing 77
drainage of abscess,
percutaneous 326
drugs see medications
dual energy mammography 180
duct (lactiferous/mammary) anatomy 234
calcification arrangement around 654
with DCIS 140, 383
enhancement 148, 148–150
filling defects or cutoff 660
carcinoma 430
galactography 87, 430
kinked, galactography 87
mammography 236
mass in, near to nipple, galactography 87
MRI 91
single dilated, as rare sign of malignancy 416
sonography 91
subareolar, importance of determining extent of invasion 397
see also extensive intraductal component; terminal ducts
carcinoma (of no specific type) 400–401, 428
mammography 428, 501
architectural distortion 618, 619, 620
asymmetry 606, 607, 628, 631
diffusely growing see diffuse growth pattern
focally growing 408, 411, 412, 414, 416, 417, 418, 419, 606, 607, 610
follow-up 425, 426, 427
histology influencing 428
implanted breast 548, 550, 551
inflammatory change 661
males 570
younger patient 667, 668, 669
MRI 136, 137, 138, 442, 449, 614, 624, 634
sonography 435, 437, 440, 637
biopsy guidance 200
correlation with histology 440
males 571
ductal carcinoma in situ (DCIS) 370–385, 386, 586
calcifications see calcifications
carcinoma vs 401–402
clinical findings and history 372
comedo-type 375, 384, 418, 643
definition 370
diagnostic methods 372–385
ductal enhancement with 140, 383
histopathology 370–371
importance and natural history 371–372
incidence 370
mammography 370, 371, 372–381, 427
MRI 135, 140, 141, 370, 381–385, 604
for local preoperative size assessment 156
non-comedo-type 375, 384
papillary see papillary carcinoma
in situ
sonography 381
biopsy guidance 202
spot compression 67
therapeutic decisions 372
younger patient 671
ductal ectasia, galactography 87
ductal epithelial proliferations, atypical 338, 340–346, 366, 621
ductal hyperplasia, atypical (ADH) 340–341, 366, 370, 371
ductal papilloma 349, 351–352, 354
ductography see galactography
ductoscopy, nipple discharge and papillary lesions 350
dye marking for preoperative localization 222
dynamic contrast-enhanced MRI see contrast-enhanced MRI
dystrophic calcifications 651
fibroadenomas 293
granulomas 328
trauma (incl. surgery)-related 495, 513, 517, 523

E

echoes and echogenicity 105, 122, 237, 266–267
carcinoma 433
echogenic halo 121
see also hyperechoic areas; hypoechoic areas; reverberation echoes
ectasia, ducal, galactography 87
ectopic glandular tissue, axillary 19, 244
edema, generalized and iatrogenic 555
edematous fibroadenomas 304
edge shadows thickened 439
thin 116
Edinburgh randomized controlled trial of screening 580
Ekland technique 71, 537, 538, 539, 539
elastography (assessment of elasticity/compressibility)
MR 182
sonographic 106–107, 122, 123, 181
carcinoma 439
emerging technologies 177–184
enhancement (in MRI) 143–151
carcinoma 399–400, 441–444
DCIS 140, 383
diffuse see diffuse enhancement
see also contrast-enhanced MRI
epithelial atypia, flat (FIA) 338, 341–345
epithelial cysts 306, 554
epithelial proliferations atypical ductal 338, 340–346, 366
benign 256
equipment (hardware)
mammography 26–39
image quality and 74–76
overview 26
sonography 100–103
European guidelines (in quality assurance)
biopsy/histopathology/ cytopathology 211
screening mammography 84–85
European Society of Mastology (EUSOMA) and implanted breast on MRI 540
on surveillance following oncoplastic surgery 544
exaggerated lateral craniocaudal view 58
exaggerated medial craniocaudal view 60
examination and findings, clinical/ physical 16–20
abscesses 321
assessment of abnormalities 19
B3 lesions (of uncertain malignant potential) fibroepithelial lesions 356, 476
lobular neoplasia and proliferations 346
Index

papillary lesions 349–350
benign non-neoplastic disorders (in general) 258, 272, 273
benign tumors/tumor-like lesions fibroadenoma 293
hamartoma 290
intramammary lymph nodes 311
lipoma 306
cysts 276
cancer 372
dense breast and palpable findings 633
documentation and reporting 78
fistulas 321
granulomatous conditions 327
males 564
cancer 569
gynecomastia 565
malignancy/semi-malignancy carcinoma 403
hematologic tumors 484–485
males 569
metastases (in breast) 487
phyllodes tumor 356, 476
sarcoma 480
normal breast adolescent 235
age-related changes 241
mature/adult 235–236
pregnancy and lactation 246
variants 242, 244
skin nodular changes 554
thickening 561
trauma (incl. surgery)-related changes 494
conserving therapy with irradiation 513
conserving therapy without irradiation 512
younger patients 665
excision see biopsy, surgical/ excisional; surgery
exposure (image receptor to radiation) 75
automatic see automatic exposure control systems
dose-related optimization of technique of 51
image quality and 75
time increases (= exposure creep) in digital mammography 52
with low-sensitivity films 48
reducing blurring 40
exposure (person to radiation) see radiation
extensive intraductal component (EIC) 444
diabetic (diabetic mastopathy) 310, 327, 328, 329, 331, 334
in fibroadenoma 299
fibrous capsule (with implants) see capsule
fibrous histiocytoma 480, 481
fiducial markers, MR-guided biopsy 207, 222
field limitation (X-ray) 75
filariasis 327
film density 51
fixture retention 78
labeling 62
processing 33, 49
dose and 52
quality 76
quality control responsibility 78
screen combinations with 30
blurring relating to 41
compared with digital mammography 34
contact optimization 78
dose and 52
magnification mammography 64
quality 76
selection 48
filter/target combination see target/ filter combination
fine needle aspiration (FNA) 187, 190, 193
accuracy 187
patient preparation 193
see also cytology
fistulas 321–326
fixture retention in film 78
flaps 509
flat epithelial atypia (FEA) 338, 341–345
focal area enhancement carcinoma 441–444
DCIS 383
nonmass 149
focal changes see localized changes
focal fibrosis 258, 310
focal growth (localized) pattern asymmetric mass 605–616
invasive carcinoma 407–420
additional foci 397–398; see also multicentricity; multifocality
direct signs 405, 407–417
indirect/secondary signs 405, 417–420
### Index

- **MRI** 445
  - recurrences (after conserving therapy + radiation) 523
  - metastases in breast 487, 489
- focal spot
  - performance evaluation 77
  - size 25–26, 40–41
- focusing in sonography 102, 105
- fog, darkroom 78
- follow-up
  - B3 lesions (of uncertain malignant potential) 339, 340
  - atypical ductal hyperplasia 341
  - flat epithelial atypia 343–344
- calcifications 657
- carcinoma, intervals 428
- time 79
- foreign body reactions/
  - granulomas 327, 328, 651
  - calcifications 651
- fungal infections 327, 331, 334

### G

- gadolinium (for enhanced MRI) 130–131
- lymph nodes 471–472
- galactoceles 284–286, 669
- galactography (ductography) 85–92
- carcinoma 430
- filling defects 87, 430, 660
- nipple discharge 169
- papillary lesions 350, 354
- preoperative localization guided by 222
- galactorrhoea 86
- galactoscopy, nipple
  - discharge 660–661
- gamma imaging 182
- gene(s), breast cancer-related 392
  - testing for 404
  - see also hereditary/familial cancer
- generator (X-ray) 74
- genetic counseling 9, 404
  - and testing 404
- geometry (in mammography) 25–26
  - blurring relating to 40, 41, 64
  - scanned slit linear detectors 38
  - giant (juvenile) fibroadenoma 292, 293, 664
- glandular tissue
  - in axilla, ectopic 19, 244
  - in mammography 235, 236
  - age-related changes 241
- compression and 53, 54
- implanted breasts 71
- photocoal positioning under tissue 33, 47
- visualization of small areas of pathology buried in tissue 53
- MRI 237
  - age-related changes 242
  - benign disorders 268
  - normal breast
    - adolescent 235
    - adult 235–237
  - palpation 17
  - sonography 235, 236
  - in HRT 248
  - gold deposits in rheumatoid arthritis 329, 471
- Gothenburg randomized controlled trial of screening 580
- grading, carcinoma 393
- granular calcifications 658
  - fine 654, 659
  - large 651–654
  - granular cell tumor 309
  - granulomas (and granulomatous conditions) 327–334
- foreign body see foreign body reactions
- lipohagic 494, 495, 507, 517, 521, 523, 526
- MRI 143, 331–334
- Grayscale Standard Display Function (of DICOM) 39
- grid (mammographic) 29, 46, 75
  - dose and 52
  - removal (gridless mammography) 29, 46
  - for magnification mammography 69
- growth patterns
  - atypical intraductal
    - ductal epithelial proliferations 340–341
- DCIS 371
- invasive carcinoma 400, 405
  - histology influencing mammographic presentation 428
  - see also specific growth patterns
  - guidance by imaging for biopsy 153–212
  - choice of modality 189–191
  - of palpable lesions in dense breast 640
- implanted breast 540–541
- male breast cancer 569
  - for preoperative localization 217–222
  - see also specific imaging or biopsy method
- gynecomastia 565–566

### H

- half-value layer measurement 77
- hamartoma 290, 595
  - histology 290
- hardware see equipment
- Health Insurance Plan (HIP)
  - randomized controlled trial of screening 580
- heart causing artifacts in MRI 144–145
- heel effect 28–29
- hemangioendothelioma 479
- hemangioma 308, 309
- hemangiopericytoma 479, 480
- hematologic and lymphoproliferative malignancies 466, 484–486
- hematomas 494, 495, 504, 505, 517, 526
  - with implantation 541
  - males 571–572
  - hemorrhage see bleeding
- HER2 positivity 402, 403
- hereditary/familial cancer
  - breast 392, 403–404, 430
  - and dense breasts without symptoms, diagnostic strategy and goals 633
  - MRI screening 154
  - risk assessment 8, 9
  - special diagnostic problems 430
  - younger patient, mammography 669
  - ovarian 9, 154, 392, 403–404
  - see also genes; genetic counseling
- high-risk lesions, underestimated, lower rate with vacuum-assisted biopsy 188
- high-risk women 403–404
  - with dense breasts and no symptoms, diagnostic strategy and goals 633
  - genetic factors see hereditary/familial cancer
  - screening 394
  - MRI 152–156, 396, 448
Index

younger 672
HIP randomized controlled trial of screening 580
histiocytoma, fibrous 480, 481
histology (normal breast) adolescents 235
adult 235
age-related changes 241
pregnancy and lactation 246
histopathology (of specimen) 186, 210–212, 594, 596–597
B3 lesions (of uncertain malignant potential) 340
atypical ductal hyperplasia 340
fibroepithelial lesions incl. phyllodes tumors 356
flat epithelial atypia 341–345
lobular proliferations/neoplasia 345, 368
papillary lesions 349, 354
radial scar 346
benign non-neoplastic disorders 256–258, 272
benign tumors/tumor-like lesions
hamartoma 290
intramammary lymph nodes 311
pseudoangiomatous stromal hyperplasia 309
biopsy for see biopsy
carcinoma in situ 400
ductal 370–371
correlation with imaging 64, 210–212
cysts 276
granulomatous conditions 327
gynecomastia 565
implanted breast 540–541, 547–551
interpretation 210–212
in local preoperative staging 157
males
cancer 567
gynecomastia 565
malignant/semi-malignant lesions
carcinoma see carcinoma
hematologic tumors 484
males 567
metastases (in breast) 487
phyllodes tumor 476
sarcoma 480
measures preceding 186
in nipple discharge 660
pathognomonic findings 593–597
trauma (incl. surgery)-related changes 494
younger patient 664–665
history-taking (incl. medical history) 5–11
carcinoma 403
cysts 276
DCIS 372
dynamic contrast-enhanced MRI and 132–134
fibroadenoma 293
inflammatory change 661–663
skin thickening 561
hormonal causes of gynecomastia 566
hormonal influences on dynamic contrast-enhanced MRI 132, 145
hormonal risk factors endogenous 9
exogenous 8, 9–10, 11
hormone replacement therapy (HRT) 10, 11, 248
asymmetry relating to 632
mammography and 428
screening 260
MRI and 132, 248, 269
hypercellular carcinoma 440
hypercellular fibroadenomas 293, 304, 440
hyperchoic areas 112, 113, 237, 241
axilla 113
benign disorders 266, 268
carcinoma 432, 433, 436, 437, 438
silicone granulomas 331
hyperemia 514
in pregnancy or lactation 672
radiation-induced 513
hyperplasia
atypical ductal (ADH) 340–341, 366, 370, 371
atypical lobular 345–346
columnar cell, with atypia 338, 341–345
pseudoangiomatous stromal 309
younger patient 664
hypersensitivity see allergy and hypersensitivity
hyperchoic areas/tissue 237, 266–267, 281
benign disorders (in general) 266–268
carcinoma 98–99, 432, 433, 435, 436
differentiation from other lesions 441
histology and 440
cysts 281
fatty tissue 112, 237, 241
in mammographically dense breasts with palpable lesions 636
mastitis 319
young patient 669

image (dynamic contrast-enhanced MRI) interpretation criteria 128–129
image (mammographic) contrast see contrast phantom, testing with 78
presentation and processing 38–39
quality
hardware factors influencing 74
responsibility for assessing 77
receptors 29–38
distance from source to (SID) 25–26
repeat analysis 78
avoiding too many 52
sharpness see sharpness viewing see viewbox
image (sonographic)
labeling 109
quality 101
near field 102
immunohistochemistry, core needle biopsy specimen 187–188
implanted/augmented breasts 535–552
anatomical placement 535
automatic exposure control systems with 47
calciﬁed fat necrosis 648
complications 541–544
rupture 538, 539, 540, 542–544, 544
histopathology 540–541, 547–551
mammography see mammography
MRI with 162, 540
capsular complications 542, 542–544
for evaluation of complications (incl. failure) 134, 162
after reconstructive surgery 159–160
positioning and views 71–72, 535, 538
invasive carcinoma see carcinoma
inversion of nipple 11, 17, 244
involution 257
adenosis and 257
mammography 241
sonography 241

J
juvenile (giant) fibroadenoma 292,
293, 664
juvenile papillomatosis 664, 665,
666, 670

K
“keyhole” sign 542, 545
kilovoltage
accuracy and reproducibility
responsibilities 77
peak 28, 44–45
magnification
mammography 64

L
labeling
mammographic film 62
sonographic image 109
lactation 246
breast cancer concurrent in 665
hyperemia associated with 672
mammography 246, 666, 672
sonography 246, 669
laser in computed radiography 37
lateral cranio-caudal view,
exaggerated 58
lateral resolution in
sonography 102–103
lateral view, 90° 58
law and carcinoma detection 395
lawnmower pattern of sonographic
examination 105
lead time bias in screening
mammography 587
legal issues, carcinoma
detection 395
leiomyoma 306
leiomyosarcoma 480, 482
length–time time bias in screening
mammography 587
leukemia 466, 484
linear enhancement, nonmass 148
“linguini” sign 544
lipoma 306, 308, 595
males 572
lipomatous metaplasia 306
lipohagic granuloma 494, 495,
507, 517, 521, 523, 526
liposarcoma 480, 481
lobular carcinoma
calcification, rarity 643
mammography 423
architectural distortion 622
histology influencing 428
implanted breast 538
spot compression 68
MRI 396, 444
sonography 437, 439, 639
histology correlating with 440
lobular carcinoma in situ; LCIS (and
lobular intraepithelial neoplasia;
LN) 338, 345–346, 366–367, 386
lobular hyperplasia,
atypical 345–346
lobular pattern of calcifications 265
lobular units, terminal duct 234,
256, 276
lobulated mass, mammography 406,
407, 431
lobules
anatomy 234
fat-containing see fat lobules
local anesthesia
biopsy 192, 198
galactography 86
preoperative localization 217
side-effects (incl. allergy) 192,
217
local staging see staging
localization 186, 215–229
documentation 186
image guidance in see guidance
preoperative 215–229, 397–398
of additional foci of
carcinoma 397–398
definition 216
indication 216
materials 222–227
methods and
technique 217–222
MRI for 222, 442, 444–445, 445
problems and
solutions 227–228
purpose 216
side effects 216–217
localized changes (focal changes)
conserving surgery with
irradiation
mammography 514, 514–517
sonography 523–526
lymph node(s) (other tissue) 272, 632–633
lymphangioma 308, 309
lymphangiosarcomas 480
lymphatic stasis 489, 555, 561
lymphoproliferative malignancies (incl. lymphoma) 466, 484–486

M
macrocysts 257
macromastia 242–244
magnetic resonance elastography 182
magnetic resonance imaging (MRI) 128–175, 181–182, 237–240, 596
abscesses 326
accuracy see accuracy
angiomas 309
architectural distortion 615
B3 lesions (of uncertain malignant potential) 341
atypical intraductal epithelial proliferations 341
fibroepithelial lesions incl. phyllodes tumors 359–360, 479
lobular neoplasia and proliferations 345, 368
papillary lesions 350, 354
radial scar 348
benign non-neoplastic disorders of benign disorders 189, 207–210
biopsy guided by core needle 189–190
for local preoperative staging 157
vacuum-assisted 188–189, 191, 207, 210
calcifications 272, 643
carcinoma in situ ductal see ductal carcinoma in situ
poorly differentiated, next to invasive carcinoma 445
contrast-enhanced see contrast-enhanced MRI
cysts see cysts
dense breasts
asymptomatic women 269–272, 632–633
palpable lesions 640
diagnostic criteria 134–151
diagnostic problem solving 169
diffusion-weighted see diffusion-weighted MRI
duct 91

fibroepithelial mixed tumors 304
fibroadenoma 142, 143, 304
fistulas 326
focal fibrosis 310
granulomas 143, 331–334
HRT and 132, 248, 269
implants see implanted breasts
lymph nodes see lymph nodes males 564
malignancy/semi-malignancy carcinoma see carcinoma fibromatosis 479
hematologic tumors 486
metastases (in breast) 489
phyllodes tumor 359–360, 479
sarcoma 481
search for unknown primary 152, 448, 609, 640
mastitis 319
normal breast 237–240
age-related changes 242
HRT effects 248
inverted nipple 244
pregnancy and lactation 246
patient information 5
patient selection and indications 129, 151–169
preoperative (for localization) 222, 397–398, 442, 444–445, 445
purpose/possibilities/limitations 128–129
scarring 169, 505, 509, 526, 528
scheduling 4, 132–134
screening see screening MRI
symmetry and see symmetry technique 128, 129–132
trauma (incl. surgery-related changes) 505–507
conserving surgery with irradiation 514, 526–529
reconstructive surgery 509
reduction mammoplasty 507
younger patients 672
magnetic resonance spectroscopy (proton spectroscopy) 132, 182
neoadjuvant chemotherapy monitoring 166, 399–400, 448
magnification mammography 29, 41, 46–47, 48, 64–70, 74
advantages 69–70
calcifications 642
DCIS 375, 376, 379
definition 64
disadvantages 70
fibroadenoma 658
ductal carcinoma in situ 370, 371, 372–381, 427
equipment overview 26
fistulas 321, 325, 326
galactoceles 284, 595
image see image
implanted breasts 535–538
of complications 542, 544, 544–547
positioning and views 71–72, 535, 538
indications/purpose 22
inflammatory change 432, 661–663
lymph nodes see lymph nodes
magnification see magnification mammography
malignancy/semi-malignancy adenomyoepithelioa 480
adenoma see carcinoma
fibromatosis 479
hematologic tumors 485–486
males 569, 569–571
mastectomy (breast) 487–489
phylloides tumor 356–359, 477
sarcoma 480
mastitis 317–319
normal breast 236, 564
adolescent 235
age-related changes on 241
HRT effects 248
pregnancy and lactation 246, 672
variants 242, 244
of palpable lesions in dense breast 636
patient information 4, 53
positioning and views 54–60, 217
additional 57–60
implanted breasts 71–72, 535, 538
importance of optimized positioning 56–57
labeling abbreviations 62
in standard mammography 54–57
positron emission 182–183
preoperative localization by 216, 217–221
questionnaire 5
reporting and documentation 80–85
scheduling 4
screening see screening mammography
sensitivity see sensitivity
skin nodular changes 554
thickening 561
sonographic biopsy guidance of microcalcifications detected by 189
specific requirements and solutions 40–52
specificity see specificity
symmetry and see symmetry
symptoms and 50–51
technique 25–40
trauma (incl. surgery)-related changes 495–504
conserving surgery with irradiation 513, 514–523
reconstructive surgery 509
reduction mammoplasty 507
unit assembly evaluation 77
younger patients 665–669
pregnancy and lactation 246, 666
see also scintimammography
Mammography Quality Assurance Act/MQSA (US) 76
mammoplasty augmentation see implanted/augmented breasts
reduction 507–509
manual adjustment with automatic exposure control systems 47, 75
manual localization, mammographically guided 220–221
margins/demarcation mammography, description 80
sonography carcinoma 433
description 121
masses (solid) cystic see cysts
DCIS presenting rarely as 379, 380
ill-defined/not smoothly outlined, differential diagnosis 604–615
interpretation/description 80
smoothly outlined, differential diagnosis 597–604
sonography 118–123, 599–602
BI-RADS 123
differentiation 98
tumor-like 289–313
<table>
<thead>
<tr>
<th>Page</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>316–320, 663</td>
<td>chronic/“plasma cell” 87, 256, 316, 317, 319, 404, 504, 646, 651, 652, 653, 655 skin thickening 560, 562</td>
</tr>
<tr>
<td>236</td>
<td>mastectomy</td>
</tr>
<tr>
<td>75</td>
<td>mastitis 316–320, 663</td>
</tr>
<tr>
<td>690</td>
<td>microcalcifications see calcifications</td>
</tr>
<tr>
<td>257</td>
<td>microcysts 257 milk of calcium in 265, 595</td>
</tr>
<tr>
<td>244</td>
<td>micropapillary DCIS 370, 371, 375, 654 milk of calcium in microcysts 265, 595 retention 246</td>
</tr>
<tr>
<td>237</td>
<td>milky diffuse enhancement 237, 269</td>
</tr>
<tr>
<td>23</td>
<td>minimal sign interval cancer 23 mixed tumors, fibroepithelial 292–306 mobility, ultrasound testing of 106, 122, 123 carcinoma 439 see also motion modulation transfer function 41 moles 554 molybdenum target and filter 27, 44, 75 morphology see shape mortality reduction by screening 50, 578, 581, 587 morula-type calcifications 83, 265, 656 motion (patient) in mammography, blurring due to 40, 41 in MRI, incorrect subtraction due to 144 mucinous (colloid) lesions 360 carcinoma 401 histology correlating with sonographic presentation 440 histology influencing mammographic presentation 428 multiplicity cancer 397 definition 397 MRI 156, 158, 395, 396, 396–397 ductal carcinoma in situ 653 multifocality (cancer) 396 MRI 156, 158, 395, 635 multiple lesions 604 indeterminate, MRI 169 myoblastoma 309 myoepithelial flaps 509 myoepithelial proliferations (benign) 256 myofibroblastoma 306, 308 myxoid fibroadenoma 295</td>
</tr>
<tr>
<td>260</td>
<td>N National Breast Screening Study (Canada) screening 580 near field, sonographic image quality in 102 needle biopsy see biopsy needlelike calcifications 646, 651, 652, 653 negative calls in screening mammography 588 false 23 neoadjuvant chemotherapy 216, 399–400, 512 monitoring 399–400 MRI 162–166, 399–400, 448 neoplasms see benign tumors; cancer; tumor Netherlands screening study 581 neu (HER2) positivity 402, 403 neurofibroma 306, 559 new technologies 177–184 90° lateral view 58 90° mediolateral view, calcifications (benign causes) 265 nipples discharge see discharge ductal mass near, galactography 87 examination/observation 11, 17 cancer 404 invasion by carcinoma 417 importance of determining 397 inverted 11, 17, 244 MRI 237 Paget disease 402, 404, 430 papillary adenoma 349 retraction 404, 417, 420, 640 galactography 87 MRI 169 sonography 237 supernumerary 244 nodularity/nodular pattern 17, 258, 260, 261, 262, 263, 267 adenosis 263, 608 adolescents 235 carcinoma 400, 405, 406, 412, 437, 439, 440 DCIS 401, 610 gynecomastia 566</td>
</tr>
<tr>
<td>75</td>
<td>mastodinia 258 “mastopathia” see fibrocystic change</td>
</tr>
<tr>
<td>665</td>
<td>medical conditions c</td>
</tr>
<tr>
<td>77</td>
<td>medical physicists’ responsibilities</td>
</tr>
</tbody>
</table>
| 60 | mediastinal obstruction 560 medical conditions contraindicating biopsy 192 medical history see history-taking medical physicists’ responsibilities (for quality) 77 medications/drugs biopsy and awareness of 192–193 biopsy contraindicated with 192 gynecomastia caused by 566 medicolegal issues, carcinoma detection 395 mediolateral 90° view, calcifications (benign causes) 265 mediolateral oblique view 54–56 lesion location determined in 83 spot compression 66 medullary carcinoma 401 histology correlating with sonographic presentation 440 histology influencing mammographic presentation 428 men see males menstrual cycle clinical examination and 236 mammography and 54, 236, 260 MRI and 240, 269 dynamic contrast-enhanced 132 metaplasia, lipomatous 306 metastases in breast 487–489 in lymph nodes see lymph node metastases of unknown origin see primary tumor, unknown microbiology, granulomatous disease 327 myoepithelial flaps 509 myoepithelial proliferations (benign) 256
<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>hematologic tumors</td>
<td>485</td>
</tr>
<tr>
<td>mass (in general)</td>
<td>406</td>
</tr>
<tr>
<td>metastases in breast</td>
<td>487, 488</td>
</tr>
<tr>
<td>pseudoangiomatous stromal hyperplasia</td>
<td>309</td>
</tr>
<tr>
<td>skin</td>
<td>554</td>
</tr>
<tr>
<td>noise</td>
<td>49–50</td>
</tr>
<tr>
<td>with low-dose screen–film systems</td>
<td>48, 49</td>
</tr>
<tr>
<td>non-comedo-type DCIS</td>
<td>375, 384</td>
</tr>
<tr>
<td>non-Hodgkin lymphoma</td>
<td>484, 485, 486</td>
</tr>
<tr>
<td>nonmass enhancement</td>
<td>148–150</td>
</tr>
<tr>
<td>normal breast</td>
<td>234–253</td>
</tr>
<tr>
<td>adolescent</td>
<td>235</td>
</tr>
<tr>
<td>adult</td>
<td>235–240</td>
</tr>
<tr>
<td>age-related changes</td>
<td>241–242</td>
</tr>
<tr>
<td>anatomy</td>
<td>234, 256</td>
</tr>
<tr>
<td>males</td>
<td>564</td>
</tr>
<tr>
<td>variant</td>
<td>242–244</td>
</tr>
<tr>
<td>HRT and see hormone replacement therapy</td>
<td></td>
</tr>
<tr>
<td>males</td>
<td>564</td>
</tr>
<tr>
<td>pregnancy and lactation</td>
<td>246</td>
</tr>
<tr>
<td>nuclear medicine</td>
<td>182–183</td>
</tr>
<tr>
<td>nutritional risk factors</td>
<td>8, 10</td>
</tr>
<tr>
<td>obesity as risk factor</td>
<td>10</td>
</tr>
<tr>
<td>oblique view</td>
<td></td>
</tr>
<tr>
<td>with customized settings</td>
<td>60</td>
</tr>
<tr>
<td>mediolateral view</td>
<td></td>
</tr>
<tr>
<td>mediolateral oblique view</td>
<td></td>
</tr>
<tr>
<td>observation</td>
<td></td>
</tr>
<tr>
<td>occult interval cancer</td>
<td>23</td>
</tr>
<tr>
<td>oil cysts</td>
<td>284–286, 310, 494, 495, 504, 507, 517, 523, 526, 595</td>
</tr>
<tr>
<td>calcifying</td>
<td>649, 651</td>
</tr>
<tr>
<td>oil-filled implants</td>
<td>535–536</td>
</tr>
<tr>
<td>oncplastic surgery</td>
<td></td>
</tr>
<tr>
<td>reconstructive/oncoplastic surgery</td>
<td></td>
</tr>
<tr>
<td>oral contraceptives (contraceptive pill)</td>
<td></td>
</tr>
<tr>
<td>MRI and</td>
<td>132</td>
</tr>
<tr>
<td>as risk factor</td>
<td>10</td>
</tr>
<tr>
<td>orientation</td>
<td></td>
</tr>
<tr>
<td>excised specimens</td>
<td>228</td>
</tr>
<tr>
<td>in sonography</td>
<td>121</td>
</tr>
<tr>
<td>carcinoma</td>
<td>433</td>
</tr>
<tr>
<td>osteoma</td>
<td>306</td>
</tr>
<tr>
<td>ovarian cancer</td>
<td></td>
</tr>
<tr>
<td>familial/hereditary</td>
<td>9, 154, 392, 403–404</td>
</tr>
<tr>
<td>lymph node metastases</td>
<td>467</td>
</tr>
<tr>
<td>overdiagnosis in screening</td>
<td>482, 585–586</td>
</tr>
<tr>
<td><strong>P</strong></td>
<td></td>
</tr>
<tr>
<td>p53 (TP53) carriers, MRI</td>
<td>154</td>
</tr>
<tr>
<td>PACS (Picture Archiving and</td>
<td></td>
</tr>
<tr>
<td>Communications System)</td>
<td>39, 131</td>
</tr>
<tr>
<td>pads and near field image quality in</td>
<td></td>
</tr>
<tr>
<td>sonography</td>
<td>102</td>
</tr>
<tr>
<td>Paget disease of nipple</td>
<td>402, 404, 430</td>
</tr>
<tr>
<td>pain</td>
<td>640</td>
</tr>
<tr>
<td>biopsy-related</td>
<td>192</td>
</tr>
<tr>
<td>causes</td>
<td>640</td>
</tr>
<tr>
<td>palpation</td>
<td>16, 17–19</td>
</tr>
<tr>
<td>evaluation and findings</td>
<td>17–19</td>
</tr>
<tr>
<td>benign disorders</td>
<td>258</td>
</tr>
<tr>
<td>cancer</td>
<td>404, 441</td>
</tr>
<tr>
<td>dense breast</td>
<td>633–640</td>
</tr>
<tr>
<td>reporting and documentation</td>
<td>78</td>
</tr>
<tr>
<td>younger patient</td>
<td>672</td>
</tr>
<tr>
<td>problems</td>
<td>19</td>
</tr>
<tr>
<td>thickening on</td>
<td>410, 432, 447</td>
</tr>
<tr>
<td>papillary adenoma of nipple</td>
<td>349</td>
</tr>
<tr>
<td>papillary carcinoma (papillary cancer)</td>
<td></td>
</tr>
<tr>
<td>calcifications</td>
<td>658</td>
</tr>
<tr>
<td>histology influencing</td>
<td></td>
</tr>
<tr>
<td>mammographic presentation</td>
<td>428–430</td>
</tr>
<tr>
<td>intracystic</td>
<td>120, 277, 282, 407, 440</td>
</tr>
<tr>
<td>males</td>
<td>571</td>
</tr>
<tr>
<td>MRI</td>
<td>143, 407, 443, 471, 636</td>
</tr>
<tr>
<td>multifocal</td>
<td>636</td>
</tr>
<tr>
<td>nipple discharge</td>
<td>661</td>
</tr>
<tr>
<td>sonography</td>
<td>107–109</td>
</tr>
<tr>
<td>papillary carcinoma in situ</td>
<td>401</td>
</tr>
<tr>
<td>ductal</td>
<td>428–430</td>
</tr>
<tr>
<td>spot compression</td>
<td>67</td>
</tr>
<tr>
<td>papillary lesions (in general)</td>
<td>278, 282, 306, 339, 348–355</td>
</tr>
<tr>
<td>papilloma</td>
<td>306, 348–355</td>
</tr>
<tr>
<td>calcifying</td>
<td>652</td>
</tr>
<tr>
<td>intracystic</td>
<td>281, 351, 352, 440</td>
</tr>
<tr>
<td>nipple discharge</td>
<td>661</td>
</tr>
<tr>
<td>power Doppler</td>
<td>107–109</td>
</tr>
<tr>
<td>younger patient</td>
<td>665</td>
</tr>
<tr>
<td>papillomatosis</td>
<td></td>
</tr>
<tr>
<td>calcifications</td>
<td>659</td>
</tr>
<tr>
<td>juvenile</td>
<td>664, 665, 666, 670</td>
</tr>
<tr>
<td>paraffin blocks of specimen, radiography</td>
<td>73</td>
</tr>
<tr>
<td>parasitic infestations</td>
<td>327, 329, 331, 334</td>
</tr>
<tr>
<td>parenchymal mammography</td>
<td>236</td>
</tr>
<tr>
<td>ACR1–4 categorization of density</td>
<td>8, 9, 79, 241, 258, 259</td>
</tr>
<tr>
<td>conserving surgery with irradiation</td>
<td>514–517</td>
</tr>
<tr>
<td>focially growing invasive</td>
<td>417</td>
</tr>
<tr>
<td>carcinoma</td>
<td></td>
</tr>
<tr>
<td>reporting and documentation of pattern</td>
<td>79</td>
</tr>
<tr>
<td>pathognomonic findings</td>
<td>593–597</td>
</tr>
<tr>
<td>patient</td>
<td></td>
</tr>
<tr>
<td>informing see information</td>
<td></td>
</tr>
<tr>
<td>motion see motion</td>
<td></td>
</tr>
<tr>
<td>outcome, MRI for preoperative local staging</td>
<td>158</td>
</tr>
<tr>
<td>selection</td>
<td></td>
</tr>
<tr>
<td>mammography</td>
<td>22</td>
</tr>
<tr>
<td>MRI</td>
<td>129, 151–171</td>
</tr>
<tr>
<td>selection bias in screening</td>
<td></td>
</tr>
<tr>
<td>mammography</td>
<td>587</td>
</tr>
<tr>
<td>peak kilovoltage see kilovoltage</td>
<td></td>
</tr>
<tr>
<td>penetration (of radiation)</td>
<td>28–29</td>
</tr>
<tr>
<td>percutaneous biopsy see biopsy</td>
<td></td>
</tr>
<tr>
<td>percutaneous drainage</td>
<td></td>
</tr>
<tr>
<td>abscess</td>
<td>326</td>
</tr>
<tr>
<td>perforated compression</td>
<td>217–218</td>
</tr>
<tr>
<td>pericanalicular fibroadenoma</td>
<td>293, 297, 664</td>
</tr>
<tr>
<td>personal history</td>
<td>5–9</td>
</tr>
<tr>
<td>phantom images</td>
<td></td>
</tr>
<tr>
<td>mammography</td>
<td>78</td>
</tr>
<tr>
<td>MRI</td>
<td>131</td>
</tr>
<tr>
<td>photocell</td>
<td>33, 47</td>
</tr>
<tr>
<td>positioning</td>
<td>33, 47, 48, 75</td>
</tr>
<tr>
<td>craniocaudal view</td>
<td>56</td>
</tr>
<tr>
<td>photo-stimulable luminescence</td>
<td>36</td>
</tr>
<tr>
<td>phyllodes tumor</td>
<td></td>
</tr>
<tr>
<td>(cystosarcoma)</td>
<td>338, 356–360, 476–479</td>
</tr>
<tr>
<td>younger patient</td>
<td>664</td>
</tr>
<tr>
<td>physical examination see examination</td>
<td></td>
</tr>
<tr>
<td>Picture Archiving and</td>
<td></td>
</tr>
<tr>
<td>Communications Systems (PACSs)</td>
<td>39, 131</td>
</tr>
<tr>
<td>“plasma cell” (chronic mastitis)</td>
<td>87, 256, 316, 317, 319, 404, 504, 506, 646, 651, 652, 653, 655</td>
</tr>
<tr>
<td>plasminogen activator inhibitor-1 (PAI-1)</td>
<td>402</td>
</tr>
</tbody>
</table>
pleomorphism

calcifications 651–654, 655, 658, 659
LCIS 345–346, 366–370
pneumocystography 92, 282
polymastia 244
popcornlike calcifications 651
positive cells in screening
mammography, false 23, 583–584
positron emission tomography (PET)
breast 182–183
lymph nodes 472–473
posterior enhancement of
soundbeam 116
power Doppler imaging 107–109
precursors of malignancy
(premalignant lesions) 366
B3 lesions as 338, 340, 345
DCIS as 366, 367, 372, 385, 586
pregnancy 246
history-taking 11
hyperemia in 672
lesions encountered in 664–665
mammography 246, 666, 672
sonography 246, 669
prenalancy see precursors of
malignancy
preoperative/preprocedural period
biopsy 192
localization in see localization
MIR in 444–445
local staging 156–158, 396
localization 222, 397–398, 442, 444–445, 445
neoadjuvant chemotherapy
monitoring 162–166, 399–400, 448
primary tumor, unknown 602, 609
search for 640, 670
MIR in 152, 448, 609, 640
problem-solving using
mammography 22, 24–25
proliferative lesions
benign atypical 272
younger patients 664
see also epithelial proliferations
prone table, stereotactic biopsy 203
prostate cancer screening and
mammographic screening,
comparisons 588
proton spectroscopy see magnetic
resonance spectroscopy
pseudoangiomatous stromal
hyperplasia 309
pseudcapsule
of hamartoma 290
sonography of 120
pseudoenancement (MRI) 144
pulse sequences
MRI
enhanced MRI 130
unenhanced MRI 131
sonography 130
punctate calcifications,
scattered 265

Q

quality 75–78
image see image
radiation see radiation
in views, criteria for
craniocaudal view 56
mediolateral oblique view 56
quality assurance in
mammography 76–77, 578
European guidelines see European
guidelines
quality control
mammography 76
documentation 77
film processing 78
sonography, equipment 103
quantum noise 49
questionnaire, mammography 5

R

radial scar (complex sclerosing
lesion) 257, 261, 346–348
architectural distortion 620, 621, 623
biopsy 190, 346, 348
mammography 348, 620, 621
spot compression 67
sonography 348, 623
radiation
dose see dose
image receptor film exposure see
exposure
low-energy 25, 26, 27, 44, 51, 53
patient exposure (and its
risks) 50
in childhood 9
in nuclear medicine 182, 183
patient fear 4
protection 75
in screening
mammography 583
quality 51, 85
determining contrast 44
image quality and 75
optimum 51
scattering see scattering
spectrum 26–29
radiation therapy (radiotherapy/
irradiation)
changes related to 11
conserving therapy with 512–529
DCIS 372
radio-guided occult lesion
localization (ROLL) 226
radioisotopes
dual, in preoperative
localization 226
in scintigraphy 182
radiologic technologists’
responsibilities (for quality) 77,
78–79
radiotherapy see radiation therapy
reactive changes
in breast cancer 420
lymph node 469
with implants 542
RECIST (Response Evaluation Criteria
In Solid Tumors) 163
reconstructive/oncoplastic surgery
(after mastectomy) 509–511
with implants 547
surveillance following 544–547
problem-solving after,
MIR 159–160
recording see documentation
recurrence
following conservation surgery
detection and differential
diagnosis 523
ductal carcinoma in situ,
risk 371
implanted breast 551
reduction mammoplasty 507–509
regional enhancement
(nonmass) 149
DCIS 383
reporting see documentation
resolution
mammography 74
good compression
improving 52
sonography 101–102
Response Evaluation Criteria In Solid
Tumors (RECIST) 163
retraction 431–432
nipples see nipples
parenchymal, locally growing
invasive carcinoma 417
skin
in cancer 404
in conserving surgery with irradiation 517
retroareolar region see subareolar/retroareolar region
reverberation echoes 102
cysts 102, 114, 279, 281
“reversed C” sign 542
rheumatoid arthritis, gold deposits 329, 471
ringlike enhancement, carcinoma 443
risk assessment
B3 lesions (of uncertain malignant potential) 339–340
radiation dose in mammography 50–51
risk factors for cancer assessment 5–11, 259
DCIS 371–372
mammographic density as 8, 9, 259–260, 260
radiation see radiation younger patients 665
see also high-risk women
rolled views 60
rossete (morula)-type calcifications 83, 265, 656
round carcinoma 400, 407, 428
rounded calcifications, large 546

S
“salad oil” sign 544
saline-filled implants 534
sarcoïdosis 327, 328, 329, 334
sarcomas 480–484
angiosarcoma 308, 480, 481, 482, 484
scanned slit linear detectors 38
scanning laser in computed radiography 37
scars 604–614
architectural distortion see architectural distortion
alcifications 646, 651
differential diagnosis 604–614, 615
granulomas in 328, 331, 334
implanted breast 539–540
post-surgical (or other trauma) 494, 495, 505, 507, 513, 514, 517, 526
MRI with 169, 505, 509, 526, 528
radial see radial scar
scattering
calcifications 656
radiation 29
reduction 29, 45–47, 53
reduction, in magnification mammography 69
sonography echoes 105
scheduling 4
scintillator (digital detector) 35–36
scintimammography 182
scirrhous carcinoma 242, 404, 408, 444, 479
scleroderma 328, 329
sclerosed fibroadenomas 205, 302, 304
sclerosing adenosis 266, 268, 620, 650
scout film, stereotactic biopsy 204
screen see intensifying screens
screening (in general) 578–591
data and discussions 579–581
definition 578
diagnostic evaluation in addition to findings on 593–674
mortality reduction by 50, 578, 581, 587
quality assurance 578
special task 578–579
screening mammography and surveillance 22–23, 24, 50–51, 394, 428, 578–591
absolute numbers 582–583
advantages 586–589
age and 50, 581, 663, 666, 672
benign change in 260–261
biennial vs annual 50
dense breasts without increased risk 632
false positive rate 583–584
with implants 547
following oncoplastic surgery 544–547
interval cancer between see interval cancer
overdiagnosis 482, 585–586
patient information 4
quality assurance 84–85
risks 583
screening sonography and 99
sensitivity 22
screening MRI (incl. contrast) 441, 582
high-risk women 152–156, 396, 448
not recommended 151, 155–156, 441, 554, 672
for implant rupture 540
screening sonography 99, 582
sebaceous cysts, males 571
secretory site of nipple discharge, search for 660–661
segmental distribution of calcifications 654
segmental enhancement (nonmass) 149
DCIS 383
selection bias in screening mammography 587
selenium, amorphous 34–35
self-examination (BSE) 16
semicircular calcifications 651
sensitivity
carcinoma detection 393
mammography 22–23, 24–25
carcinoma 431
film development time extension causing increase in 49
low-sensitivity screen/film systems 48
MRI 156
sentinel node biopsy 39, 458
seromas 494, 495, 504, 505, 513, 517, 526
shadowing/acoustic shadows (in sonography)
benign disorders 268
carcinoma 433, 439
cysts 281
problems relating to 113
thickened edge shadows 439
thin edge shadows 116
shape/morphology (and its description and interpretation) of calcifications 643
mammographic 79, 80–82
MRI 128–129
indeterminate, retrospective ultrasound recommended 148
sonographic 121
carcinoma 433
sug recommends malignancy 651–656
sharpness (mammography) or blurring 25–26, 40–41
screen–film systems and 30
shear wave elastography 107, 181
shell-like calcifications 651
silicon, amorphous 35–36
silicone granulomas/deposits 327, 328, 331, 334, 542, 544, 651
calcifications 651
lymph nodes 471

silicone implants 534
augmentation using see
implanted/augmented breasts
silicone injections for
augmentation 535
site see localization; location
size of breast 16
automatic exposure control
systems with small
breasts 47
reporting and documentation
of increases in 79
of carcinoma 397
increase in mammogram 420
of DCIS, MRI preoperative
determination 156
skin 553–562
calcifications 646
in conserving surgery with
irradiation, mammography of
localized changes in 514–517
examination/observation for
changes 16–17
carcinoma 404
infiltration by carcinoma,
sonography 404
sonography 237
thickening 554–562
diffuse see diffuse skin changes
slice thickness in sonography 103
slot mammography 47
small breasts, automatic exposure
control systems 47
smoothly outlined density,
differential diagnosis 597–604
“snowstorm” pattern 331, 542, 544
soft density surrounding
microcalcifications, differential
diagnosis 657
soft tissue sarcomas 480, 481, 482
solid lesions see masses
sonography
(ultrasoundography) 97–125,
180–181, 197–203
abscesses 321, 325, 325–326
male 572
accuracy see accuracy
axilla see axilla; lymph nodes
B3 lesions (of uncertain malignant
potential) fibroepithelial lesions incl.
phylloides tumors 359
lobular neoplasia and
proliferations 345, 368
papillary lesions 350, 351–352
radial scar 348, 623
benign non-neoplastic disorders
see benign disorders
benign tumors/tumor-like lesions
angiosmas 309
fibroadenoma 299–304, 305, 433
focal fibrosis 310
hamartoma 290
pseudangiomatous stromal
hyperplasia 309
biopsy guided by 100, 188, 190,
197–203
carcinoma (females) 432
carcinoma (males) 569
complications 192
core needle biopsy 190,
199–200, 201–202
cyst aspiration 93
ducts 91
of mammographically detected
microcalcifications 189
calcifications see calcifications
cysts 98, 266, 268, 278, 278–282,
286, 595, 599–602
diagnostic value 98, 278,
278–282
differentiation from other solid
lesions 98
galactocele 284
guidance for aspiration 93
oil cyst 286
pneumocystography following
(with suspicious or
inconclusive cysts) 92
power Doppler 107
reverberation echoes 102, 114,
279, 281
dense breasts 632
documentation 105–124
duct 91
ductal carcinoma in situ see
ductal carcinoma in situ
equipment
requirements 105–111
examination technique 103
fistulas 321, 325, 325–326
granulomatous lesions 331
implanted breast see implanted/
augmented breast
inflammatory change 663
lesions (in general) 113–124
characteristics 121
retroreflective ultrasound with
indeterminate morphology
on MRI 148
lymph nodes see lymph nodes
males 564
benign lesions 571–572
cancer 569, 571
gynecomastia 565, 566
malignancy/semi-malignancy
adenomyoepeithelioma 480
carcinoma see carcinoma
fibromatosis 479
hematologic tumors 486
males 569, 571
metastases (in breast) 489
phylloides tumor 359, 479
sarcoma 480–481
younger patients 669, 670
mastitis 319
normal breast 112–113, 237
adolescent 235
age-related changes
in 241–242
HRT effects 248
pregnancy and lactation 246
variants 244
of palpable lesions in dense
breast 636
patient information 4
preoperative localization guided
by 221–222
purpose/possibilities/
limitations 98–100
screening 99, 582
second look (after MRI) 156, 189,
207, 222
skin thickening 561
smoothly outlined density 599–
602, 604
symmetry and see symmetry
technological
developments 180–181
trauma (incl. surgery)-related
changes 504–505
conserving therapy +
irradiation 523–526
reconstructive surgery 509
younger women see younger
women
source to image-receptor distance
(SID) 25–26
soya bean oil-filled
implants 534–535
spatial frequency filtering 39
spatial resolution in
sonography 102–103
specificity
 carcinoma detection 393–394,
431
mammography 23–24
carcinoma 431
specimen handling 210
histopathology see histopathology imaging/radiography 72–74
DCIS 374, 375, 376, 378, 379
invasive carcinoma 397
microcalcifications 73, 206
see also biopsy
spectral mammography 180
specular echoes 105
spicules and spiculated masses 495
axillary (metastatic) adenopathy 466
DCIS 373, 379, 383
invasive carcinoma 401, 406, 407, 408, 419, 428, 431
trauma (incl. surgery)-related 495
spindle cell lesions classified as B3 360
spindle cell tumor, benign (myofibroblastoma) 306, 308
spot compression 60, 62–64, 70
staging of cancer (locoregional) 395–396
lymph nodes 459
preoperative MRI for 156–158, 396
steatocystoma multiplex 310
stereotactic biopsy 203–207
complications 192
contraindications 192
male breast cancer 569
palpable lesions in dense breast 640
vacuum-assisted 191
stereotactic localization, mammographic 218–220
stenal muscle, isolated bundle 611
Stockholm County randomized controlled trial of screening 580
strain elastography 107
stromal hyperplasia, pseudoangiomatous 309
structure
diffuse changes see diffuse changes
localized changes see localized changes
in mammography
benign disorders, changes 261–265
differential diagnosis with indistinctness in 431
noise relating to 49
in sonography, of carcinoma, internal 440
subareolar/retroareolar region (incl. ducts) 360
abscess 316
in gynecomastia 565, 566
malignancy 618, 640
importance of determining involvement 397
subcutaneous mastectomy, mammography after 71, 72
subscapular artery (lateral) in lymph node sonography 461
subtraction images in MRI, patient motion affecting 144
superimposition (true lesions distinguished from)
architectural distortion 615
focal lesions 614
superior vena cava obstruction 559
supernumerary mammary glands 244
surgery (incl. excision) 493–531
B3 lesions (of uncertain malignant potential)
fibroepithelial lesions incl. phyllodes tumors 360
flat epithelial atypia 343
lobular neoplasia and proliferations 346
papillary lesions 354
radial scar 348
changes related to trauma of 11, 493–531
chemotherapy before see neoadjuvant chemotherapy
conserving see conservation DCIS 372
lymph node see lymph nodes
nipple discharge 660
oncoplastic see reconstructive/oncoplastic surgery
scarring (severe) after, MRI with 169
screening and its impact on 588
see also preoperative/
preprocedural period and specific procedures
surgical biopsy see biopsy, surgical/excisional
surveillance see screening mammography and surveillance
tissue material, calcified 504
“sweating” of implants 542
Swedish screening programs 581
randomized controlled trials 580
symmetry or asymmetry 626–632
calcifications 655
focally asymmetric mass 604–615
global 625
mammography 604–614, 626–631
carcinoma 407–416, 420, 431
description 82
MRI 632
accessory tissue 244
nipple 17
size 16
skin thickening and 555
sonography 631–632
accessory tissue 244
symptom(s)
hinting of malignancy 11
mammography and 50–51
symptomatic women
with implants
mammography 535–538
MRI 540
problem-solving in 593–674

T
tangential view 60
target/filter combination 27, 44, 44–45
quality of radiation and 51
teacup phenomenon 58, 265, 650, 651, 656
technetium-99m scan 182
technological developments 177–184
temporal resolution in MRI 130
see also time-gain compensation
terminal ducts 234
lobular units 234, 256, 276
thickened edge shadows 439
thickness (of breast) in mammography
dose and 51
increases (thickening), differential diagnosis 431, 432
palpable thickening 410, 432, 447
thin edge shadows 116
thoracic artery (lateral) in lymph node sonography 461
thoracic wall (chest wall) injury in preoperative localization 217
thoraco-acromial artery in lymph node sonography 461
digital mammography see tomosynthesis
Index

MRI 130, 131
ultrasound 181
threshold, individual examiner’s 22
thyroid hormone administration 11
time-gain compensation 104–105
see also temporal resolution
tissue transfer, autogenous 509
tomosynthesis mammography 178–179, 602–604, 614, 615
architectural distortion 615
ill-defined or focal asymmetric mass 614
smoothly outlined density 602–604
TP53 carriers, MRI screening 154
transducer (sonography) 100, 101, 102, 103, 104, 105
traztuzumab 402
trauma (injury)-related changes 493–531
surgical 11, 493–531, 493–531
trianagulation via stereotaxis 203
tubular carcinoma 401
histology influencing mammographic presentation 428
tumor, gynecomasia due to 566
see also benign tumors; cancer; primary tumor, unknown
tumor-like masses 289–313
Two County randomized controlled trial of screening 580

U
ultrasmall super-paramagnetic iron oxide (USPIO) 472
ultrasoundography see sonography
uncertain malignant potential, lesions of (B3) 211, 337–364
definition and classification 338
diagnosis see diagnosis
imaging 339
prevalence 339–340
risk 339–340
specific types of lesion 340–360
therapeutic recommendations 338–339
see also borderline lesions
unknown primary tumor see primary tumor
urokinase plasminogen activator (UPA1) 402
USPIO contrast medium (ultrasmall super-paramagnetic iron oxide) 472

V
vacuum-assisted biopsy (VABB) 187, 188–189, 191, 195–197, 596
accuracy 188–189
carcinoma 448
cysts 278
duct 91–92
ductal carcinoma in situ 385
ultrasound-guided 91
European guidelines for classification of lesions 211
flat epithelial atypia 343
intramammary lymph nodes 312
MR-guided 188–189, 191, 207, 210
patient preparation 193
radial scar 348
stereotactic 205, 206
technique 195–197
US-guided 191, 202
ducts 91
variant anatomy 242–244
vascular calcifications 651
vascularity, ultrasound assessment 122
BI-RADS and 123
vena cava obstruction, superior 559
verruca (wart) 555, 558, 595
viewbox and viewing conditions 33
responsibilities for 78
visual checklist 78
visual inspection see inspection

W
warts (verrucae) 555, 558, 595
wax reactions/granulomas 327, 328, 331, 344, 649, 651
Wegener granulomatosis 327, 328, 329, 330
windowing in digital imaging 39
wire localization 217, 226–227
CT-guided 224
MR-guided 223
stereotactic-guided 217
work sheet, physician’s 18–20

X
X-ray beam quality assessment 77
X-ray field limitation 75
X-ray generator 74
X-ray tube 25–29
power 74

Y
younger women 663–668
changes in, and their histology 664, 672
screening mammography 50, 581, 663, 666, 672
sonography 99, 669–670
pregnancy and lactation 246, 669
special considerations and problems 663–664
see also adolescent breast; childhood